Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy

All NewsMarch 30, 2026

Biogen stock rises after FDA approves high-dose Spinraza for SMA; litifilimab data adds momentum amid mixed technical signals.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent